Educational information, not medical advice — ask your doctor or midwife.
Suranjan refers to the dried corm of Colchicum luteum (or related Colchicum species) and has been a staple of Unani and Ayurvedic medicine for over a thousand years, particularly across South Asia, Persia, and the Arab world. It is most famous for its use in gout and painful, swollen joints. Two varieties are traditionally recognized — Suranjan Talkh (bitter, considered more potent) and Suranjan Shirin (sweet, considered milder and safer for everyday use).
Suranjan contains colchicine, a well-studied anti-inflammatory compound that works by interfering with the movement of white blood cells (neutrophils) into inflamed joint tissue, which is the main driver of gout pain. By reducing this cellular response, it calms the acute flare of swelling and pain. It also appears to help lower uric acid buildup over time, addressing one of gout's underlying causes.
In traditional practice, Suranjan is most often used as a dried powder (churna) mixed into formulations. Modern herbalists also use standardized extracts and tablets. The powder can be combined with honey or warm water. Suranjan Shirin (sweet variety, Colchicum luteum) is generally preferred for longer-term use due to a milder alkaloid profile.
Suranjan has been documented in classical Unani texts including Ibn Sina's Canon of Medicine (Al-Qanun fil-Tibb) as a remedy for joint pain, gout, and sciatica. In Ayurveda, it appears in texts referencing 'Hirantuthi' and has been used in compound formulations for arthritis and vata disorders for well over a millennium. The plant's active compound, colchicine, was first isolated in the 19th century and is now a globally used pharmaceutical — making Suranjan one of the clearest bridges between traditional botanical medicine and modern pharmacology.
Evidence grades and traditional-use labels are explained in our methodology. Nothing here is medical advice.
What it is typically used for, usual dose, cautions, and the study behind it where real trial data exists.
One email with the summary. We'll also send a short weekly evidence update — unsubscribe any time.